LABORATORY CORPORATION OF AMERICA HOLDINGS

Laboratory Corporation of America Holdings

Equities

LH

US50540R4092

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 04:00:02 2024-04-15 pm EDT			5-day change	1st Jan Change
203.3 ^USD	-1.17%		-3.24%	-10.55%

Apr. 15	Labcorp Introduces Test for Early Detection of Neurodegenerative Diseases	MT
Apr. 15	Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw	CI

KIYATEC, Inc. announced that it has received $18.057766 million in funding from Bruker Corporation, Laboratory Corporation of America Holdings, VentureSouth, Seae Ventures

December 11, 2022

On December 12, 2022, KIYATEC, Inc. closed the transaction. The transaction was led by new investor Bruker Corporation. The transaction also included participation from returning investors Laboratory Corporation of America Holdings, VentureSouth, and Seae Ventures.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	LABORATORY CORPORATION OF AMERICA HOLDINGS	203.3 USD	-1.17%	-3.24%	17.1B
	BRUKER CORPORATION	85.75 USD	-2.09%	-4.97%	11.81B

Latest news about Laboratory Corporation of America Holdings

Labcorp Introduces Test for Early Detection of Neurodegenerative Diseases	Apr. 15	MT
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw	Apr. 15	CI
Labcorp Keeps Quarterly Dividend at $0.72 Per Share, Payable June 12 to Stockholders of Record May 28	Apr. 11	MT
Labcorp Declares Quarterly Dividend, Payable on June 12, 2024	Apr. 11	CI
Sector Update: Health Care Stocks Slump Wednesday Afternoon	Apr. 10	MT
Labcorp Says US FDA Granted Emergency Use Authorization for Mpox Home Collection Kit	Apr. 10	MT
Labcorp Gets Emergency Authorization from FDA for Home Kit to Detect Monkeypox	Apr. 10	DJ
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit	Apr. 10	CI
Laboratory Corp of America Expands Precision Oncology Portfolio	Apr. 08	MT
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs	Apr. 08	CI
Labcorp Launches Labcorp Plasma Detect? Extending Leadership into Molecular Residual Disease Clinical Research	Apr. 05	CI
Laboratory Corporation Receives a Shareholder Proposal from People for the Ethical Treatment of Animals	Apr. 04	CI
Laboratory Corporation Receives a Shareholder Proposal from Tara Health Foundation	Apr. 04	CI
Laboratory Corporation Receives a Shareholder Proposal from John Chevedden	Apr. 04	CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $760,515, According to a Recent SEC Filing	Apr. 03	MT
Laboratory Corp Of America Holdings Insider Sold Shares Worth $1,407,387, According to a Recent SEC Filing	Apr. 03	MT
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research	Apr. 02	CI
Labcorp Expands Investment, Collaboration Pact with Xcell Biosciences	Apr. 01	MT
Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration with Labcorp	Apr. 01	CI
Prelude Network Announces Expansion of Partnership with Labcorp to Serve as Its Preferred Genetic Carrier Screening Lab	Mar. 29	CI
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	Mar. 28	MT
Laboratory Corporation of America Holdings (NYSE:LH) entered into an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.	Mar. 27	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Argus Upgrades Laboratory Corp of America Holdings to Buy From Hold, Price Target is $250	Mar. 25	MT
Laboratory Corp of America Launches PTau217 Diagnostic Test for Alzheimer's Disease	Mar. 20	MT

Chart Laboratory Corporation of America Holdings

Duration

Period

Chart Laboratory Corporation of America Holdings

More charts

Company Profile

Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows: - clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services; - development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies. Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).

Sector

Healthcare Facilities & Services

Calendar

2024-04-24 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Laboratory Corporation of America Holdings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

203.3 USD

Average target price

244.1 USD

Spread / Average Target

+20.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.55%	17.1B
CVS HEALTH CORPORATION	-12.66%	86.92B
HCA HEALTHCARE, INC.	+19.19%	85.34B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+12.75%	29.88B
FRESENIUS SE & CO. KGAA	-9.33%	15.24B
QUEST DIAGNOSTICS INCORPORATED	-6.70%	14.29B
EUROFINS SCIENTIFIC SE	+2.75%	12.38B
PURE HEALTH HOLDING	-29.82%	12.1B
DAVITA INC.	+24.05%	11.4B
NATERA, INC.	+44.35%	10.92B

Other Healthcare Facilities & Services